NCT07247110 2026-03-11
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Merck Sharp & Dohme LLC
Phase 1 Recruiting
Clinical Trials
26 trialsNCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT04717375 2025-08-07
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT03783403 2024-09-19
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
Celgene
Phase 1 Terminated
NCT06274437 2024-08-07
A Study of BND-35 in Participants With Advanced Solid Tumors
Biond Biologics
Phase 1 Recruiting
NCT03387111 2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03284502 2023-08-01
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Unknown
NCT01855451 2022-11-18
HPVOropharynx
Trans Tasman Radiation Oncology Group
Phase 3 Unknown
NCT02095054 2021-04-01
Regorafenib and Cetuximab in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01973868 2019-04-09
Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
Bayer
Phase 1 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01472016 2017-11-21
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT02316496 2017-08-01
REGAIN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Terminated
NCT00226239 2017-07-11
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
University of Pittsburgh
Phase 2 Completed
NCT01482377 2017-01-27
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Hoffmann-La Roche
Phase 1 Completed
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00110357 2015-12-24
Study of Erbituxâ„¢ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT00207077 2015-10-28
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01727869 2015-04-06
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00439517 2014-06-27
FUTURE
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT01031212 2013-05-13
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
University of California, San Francisco
Phase 1 Withdrawn
NCT01760811 2013-01-04
CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT
Rabin Medical Center
Phase 1/2 Unknown
NCT00894569 2009-05-14
PACET-CUP
Heidelberg University
Phase 2 Unknown